Repurposing drugs in oncology (ReDO) - Clarithromycin as an anti-cancer agent

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Van Nuffel, An M T ^a   Sukhatme, Vidula ^b   Pantziarka, Pan ^a,c   Meheus, Lydie ^a   Sukhatme, Vikas P ^b,d   Bouche, Gauthier ^a  

^a Anticancer Fund   (Belgium)

^b GlobalCures Inc   (United States)

^c George Pantziarka TP53 Trust   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti bacterial agents; Antineoplastic agents; Clarithromycin; Drug repositioning; Neoplasms; ReDO project

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CLARITHROMYCIN; DEXAMETHASONE; TRANSCRIPTION FACTOR;

ABDOMINAL PAIN; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CONFUSION; DIARRHEA; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG REPOSITIONING; DYSGEUSIA; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSOMNIA; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMNOLENCE; TUMOR MICROENVIRONMENT; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84923325297     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.513     Document Type: Article

References (129)

1. Kanoh S and Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clin Microbiol Rev 23(3) pp 590-615 DOI: 10.1128/CMR.00078-09 PMID: 20610825 PMCID: 2901655
2. Schwartz H et al (1998) Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens Am J Gastroenterol 93(4) pp 584-90 DOI: 10.1111/j.1572-0241.1998.169-b.x PMID: 9576452
3. Varvyanskaya A and Lopatin A (2014) Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery Int Forum Allergy Rhinol 4(7) pp 533-41 DOI: 10.1002/alr.21318 PMID: 24659566
4. 5HerathSC and Poole P (2013) Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) Cochrane Database Syst Rev 11 pp CD009764 PMID: 24288145
5. Kadota J et al (2003) Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis Respir Med 97(7) pp 844-850 DOI: 10.1016/S0954-6111(03)00042-8 PMID: 12854636
6. Gluud C et al (2008) Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease Cardiology 111(4) pp 280-7 DOI: 10.1159/000128994 PMID: 18451646 PMCID: 2820332
7. Schembri S et al (2013) Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies BMJ (Clinical research ed) 346 pp f1235
8. Winkel P et al (2011) Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology 118(1) pp 63-7 DOI: 10.1159/000324533 PMID: 21447948
9. Zhanel GG et al (2001) Review of macrolides and ketolides: focus on respiratory tract infections Drugs 61(4) pp 443-98 DOI: 10.2165/00003495-200161040-00003 PMID: 11324679
10. Chu SY, Deaton R and Cavanaugh J (1992) Absolute bioavailability of clarithromycin after oral administration in humans Antimicrob Agents Chemother 36(5) pp 1147-50 DOI: 10.1128/AAC.36.5.1147 PMID: 1387301 PMCID: 188854
11. Benninger P et al (2004) A comparative clarithromycin bioavailability study: determination of clarithromycin and 14-(R)-hydroxyclarithromycin under fasting and fed conditions Int J Clin Pharmacol Ther 42(6) pp 342-9 DOI: 10.5414/CPP42342 PMID: 15222728
12. Zuckerman JM et al (2011) Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline)Med Clin North Am 95(4) pp 761-91 viii DOI: 10.1016/j.mcna.2011.03.012 PMID: 21679791
13. Hamada K et al (2000) Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer Chemotherapy 46(1) pp 49-61 DOI: 10.1159/000007256
14. Yatsunami J et al (1999) Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells Clin Exp Metastasis 17(4) pp 361-7 PMID: 10545023
15. Ohara T et al (2004) Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice Anticancer Res 24(6) pp 3723-30
16. Yatsunami J et al (1997) Clarithromycin is a potent inhibitor of tumor-induced angiogenesis Res Exp Med (Berl) Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 197(4) pp 189-97 DOI: 10.1007/s004330050068 PMID: 9440137
17. Yatsunami J et al (1999) Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells Cancer Lett 147(1-2) pp 17-24 DOI: 10.1016/S0304-3835(99)00258-X
18. Sassa K et al (1999) Therapeutic effect of clarithromycin on a transplanted tumor in rats Antimicrobial Agents Chemother 43(1) pp 67-7219.
19. Sassa K, Mizushima Y and Kobayashi M (1999) Differential modulatory effects of clarithromycin on the production of cytokines by a tumor Antimicrob Agents Chemother 43(11) pp 2787-9 PMID: 10543765 PMCID: 89561
20. Nakajima M et al (1993) Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma Cancer Res 53(23) pp 5802-7 PMID: 8242639
21. Welch DR, Fabra A and Nakajima M (1990) Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential Proc Natl Acad Sci U.S.A. 87(19) pp 7678-82 DOI: 10.1073/pnas.87.19.7678 PMID: 2217201 PMCID: 54811
22. Nakamura M et al (2010) Clarithromycin attenuates autophagy in myeloma cells Int J Oncol 37 pp 815-20 PMID: 20811702
23. Moriya S et al (2013) Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells Int J Oncol 42(5) pp 1541-50 PMID: 23546223 PMCID: 3661227
24. Komatsu S et al (2012) Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells Int J Oncol 40(4) pp 1029-39
25. Komatsu S et al (2013) Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells Biochem Biophys Res Commun 437(1) pp 41-7 DOI: 10.1016/j.bbrc.2013.06.032 PMID: 23792097
26. Schafranek L et al (2013) Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy Leuk Lymphoma 54(1) pp 198-201 DOI: 10.3109/10428194.2012.698737
27. Carella AM et al (2012) Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia Leuk Lymphoma 53(7) pp 1409-11 DOI: 10.3109/10428194.2012.656105 PMID: 22233113
28. Durie BGM et al (1997) Clarithromycin (Biaxin) as primary treatment for myeloma Blood 90(279a) pp abstr suppl 1
29. Musto P et al (2002) Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report Haematologica 87(6) pp 658-59 PMID: 12031924
30. Morris TC, Ranaghan L and Morrison J (2001) Phase II trial of clarithromycin and pamidronate therapy in myeloma Med Oncol (Northwood, London, England) 18(1) pp 79-84 DOI: 10.1385/MO:18:1:79
31. Stewart AK et al (1999) Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma Blood 93(12) pp 4441 PMID: 10391696
32. Moreau P et al (1999) Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Franc¸ais du Myélome (IFM) Leukemia 13(3) pp 490-1 DOI: 10.1038/sj.leu.2401332 PMID: 10086745
33. Vescio RA (2001) American Society of Hematology meeting Blood 98 pp abstract 5007
34. Coleman M et al (2002) BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia Leuk Lymphoma 43(9) pp 1777-82 DOI: 10.1080/1042819021000006303
35. Dimopoulos MA et al (2003) Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone Semin Oncol 30(2) pp 265-9 DOI: 10.1053/sonc.2003.50079 PMID: 12720150
36. Coleman M et al (2003) Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone Semin Oncol 30(2) pp 270-4 DOI: 10.1053/sonc.2003.50044 PMID: 12720151
37. Niesvizky R et al (2003) Dexamethasone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin on response rate. Interim results of a prospective, sequential, randomized Trial Blood 102(11) pp 237a Ember 16
38. Morris et al (2008) Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma Br J Haematol 143(3) pp 349-54 DOI: 10.1111/j.1365-2141.2008.07360.x PMID: 18759764
39. Knight R (2005) IMiDs: a novel class of immunomodulators Semin Oncol 32(4 Suppl 5) pp S24-30 DOI: 10.1053/j.seminoncol.2005.06.018 PMID: 16085014
40. Niesvizky R et al (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma Blood 111(3) pp 1101-9 DOI: 10.1182/blood-2007-05-090258
41. Rossi et al (2013) BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma Blood 121(11) pp 1982-5 DOI: 10.1182/blood-2012-08-448563 PMID: 23299315 PMCID: 3596960
42. Rajkumar SV (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106(13) pp 4050-3 DOI: 10.1182/blood-2005-07-2817 PMID: 16118317 PMCID: 1895238
43. Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11(1) pp 29-37 DOI: 10.1016/S1470-2045(09)70284-0
44. Gay F et al (2010) Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma Am J Hematol 85 (9) pp 664-9 DOI: 10.1002/ajh.21777 PMID: 20645430 PMCID: 3956597
45. Kato H et al (2013) Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide Ann Hematol 92(12) pp 1711-2 DOI: 10.1007/s00277-013-1761-x PMID: 23625297
46. Ghosh N et al (2014) Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma Am J Hematol 89(8) pp E116-20 DOI: 10.1002/ajh.23733 PMID: 24723438
47. Mark TM et al (2014) Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma Leuk Lymphoma 55(12) 2842-9 DOI: 10.3109/10428194.2014.896005 PMID: 24576165
48. Rossi AC et al (2012) Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma J Clinical Oncol 30 pp (suppl; abstr 8036)\
49. Mark T et al (2012) ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma ASH Annual Meeting pp abstract 77
50. Fischbach W (2004) Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series Gut 53(1) pp 34-7 DOI: 10.1136/gut.53.1.34
51. Ruskone-Fourmestraux A (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment Gut 48(3) pp 297-303 DOI: 10.1136/gut.48.3.297 PMID: 11171816 PMCID: 1760135
52. Cavanna L et al (2008) High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature World J Surg Oncol 6 pp 35 DOI: 10.1186/1477-7819-6-35 PMID: 18353178 PMCID: 2329637
53. Chen LT et al (2001) Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach J Clinic Oncol 19(22) pp 4245-51
54. Chen LT et al (2005) Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma J Natl Cancer Inst 97(18) pp 1345-53 DOI: 10.1093/jnci/dji277 PMID: 16174856
55. Salam I et al (2001) Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication Eur J Gastroenterol Hepatol 13(11) pp 1375-8 DOI: 10.1097/00042737-200111000-00018 PMID: 11692066
56. Morgner A et al (2001) Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection J Clin Oncol 19(7) pp 2041-8 PMID: 11283137
57. Alsolaiman MM et al (2003) Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection Gut 52(4) pp 507-9 DOI: 10.1136/gut.52.4.507 PMID: 12631659 PMCID: 1773612
58. Sugimoto M et al (2001) Regression of primary gastric diffuse large B-cell lymphoma after eradication of Helicobacter pylori Gastrointest Endosc 54(5) pp 643-5 DOI: 10.1067/mge.2001.118647 PMID: 11677489
59. Kuo SH et al (2012) Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas Blood 119(21) pp 4838-44 quiz 5057 DOI: 10.1182/blood-2012-01-404194 PMID: 22403257
60. Ferreri AJ et al (2012) Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial Blood 120(18) pp 3858-60 DOI: 10.1182/blood-2012-06-438424 PMID: 23118214
61. Sauter C and Blum S (2003) Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease Am J Clin Oncol 26(1) pp 92-4 DOI: 10.1097/00000421-200302000-00018 PMID: 12576932
62. Inoue F and Chiba T (1999) Regression of MALT lymphoma of the rectum after anti-H pylori therapy in a patient negative for H pylori Gastroenterology 117(2) pp 514-5 DOI: 10.1053/gast.1999.0029900514b PMID: 10465640
63. Arima N and Tsudo M (2003) Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy Brit J Haematol 120(5) pp 790-2 DOI: 10.1046/j.1365-2141.2003.04170.x
64. Ochi M et al (2006) Regression of primary low-grade mucosa-associated lymphoid tissue lymphoma of duodenum after longterm treatment with clarithromycin Scand J Gastroenterol 41(3) pp 365-9 DOI: 10.1080/00365520500331224 PMID: 16497629
65. Govi S et al (2010) Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial Br J Haematol 150(2) pp 226-9 PMID: 20433679
66. Ishimatsu Y et al (2010) Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin Chest 138(3) pp 730-3 DOI: 10.1378/chest.09-2358 PMID: 20822996
67. Saad AS (2014) An open-label randomized controlled phase II study of clarithromycin (CL) plus CVP in patients (pts) with previously untreated stage III/IV indolent non Hodgkin lymphoma (NHL) J Clin Oncol 32(suppl 3) pp abstr e19510
68. Ohe M and Hashino S (2011) A case of follicular B-cell lymphoma treated using clarithromycin Korean J Hematol 46(3) pp 203-6 DOI: 10.5045/kjh.2011.46.3.203 PMID: 22065978 PMCID: 3208206
69. Ohe M, Hashino S and Hattori A (2012) Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone Korean J Hematol 47(4) pp 293-7 DOI: 10.5045/kjh.2012.47.4.293
70. Ohe Mi and Hashino S (2013) Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide Korean J Inter Med 28(3) pp 377-9 DOI: 10.3904/kjim.2013.28.3.377
71. Mikasa K et al (1997) Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin Chemotherapy 43(4) pp 288-96 DOI: 10.1159/000239580 PMID: 9209786
72. Sakamoto M et al (2001) Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer Chemotherapy 47(6) pp 444-51 DOI: 10.1159/000048556
73. Hirata T et al (2004) Suppression of postoperative systemic inflammatory response syndrome with clarithromycin following lung cancer surgery Eur Surg Res 36(1) pp 13-9 DOI: 10.1159/000075069 PMID: 14730218
74. Chow LW et al (2000) Clarithromycin attenuates mastectomy-induced acute inflammatory response Clinical Diagn Lab Immunol 7(6) pp 925-31
75. Ishimatsu Y et al (2004) Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro Int J Antimicrob Agents 24(3) pp 247-53 DOI: 10.1016/j.ijantimicag.2004.03.022 PMID: 15325428
76. Ichiyama T et al (2001) Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells Antimicrob Agents Chemother 45(1) pp 44-7 DOI: 10.1128/AAC.45.1.44-47.2001
77. Kuo SH et al (2004) Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas J Clin Oncol 22(17) pp3491-7 DOI: 10.1200/JCO.2004.10.087 PMID: 15337797
78. Chen Y et al (2010) Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases Am J Clin Pathol 133(2) pp 305-13 DOI: 10.1309/AJCP4H6ADGYDZMOA PMID: 20093241
79. Ohashi S et al (2000) A clinicopathologic study of gastric mucosa-associated lymphoid tissue lymphoma Cancer 88(10) pp 2210-9 DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2210::AID-CNCR3>3.0.CO;2-I PMID: 10820341
80. Fukui T et al (2004) Immunogenetic analysis of gastric MALT lymphoma-like lesions induced by Helicobacter pylori infection in neonatally thymectomized mice Lab Invest 84(4) pp 485-92 DOI: 10.1038/labinvest.3700056 PMID: 14968120
81. Morgner A et al (2001) Helicobacter-induced expression of Bcl-X(L) in B lymphocytes in the mouse model: a possible step in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma Int J Cancer 92(5) pp 634-40 DOI: 10.1002/1097-0215(20010601)92:5<634::AID-IJC1241>3.0.CO;2-V PMID: 11340565
82. Mizunoe S et al (2004) Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL Int Immunopharmacol 4(9) pp 1201-7 DOI: 10.1016/j.intimp.2004.05.011 PMID: 15251115
83. Semino-MC et al (2013) Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution Clin Cancer Res 19(14) pp 3966-76 DOI: 10.1158/1078-0432.CCR-13-0616
84. Zhang W and Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells Cell Res 12(1) pp 9-18 DOI: 10.1038/sj.cr.7290105 PMID: 11942415
85. Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 298(5600) pp 1911-2 DOI: 10.1126/science.1072682PMID: 12471242
86. Shinkai M et al (2006) Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression Antimicrob Agents Chemother 50(5) pp 1738-44 DOI: 10.1128/AAC.50.5.1738-1744.2006 PMID: 16641444 PMCID: 1472217
87. Webb CP et al (1998) Signaling pathways in Ras-mediated tumorigenicity and metastasis Proc Natl Acad Sci U.S.A. 95(15) pp 8773-8 DOI: 10.1073/pnas.95.15.8773 PMID: 9671754 PMCID: 21152
88. Mishima K, Inoue K and Hayashi Y (2002) Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma Oral Oncol 38(5) pp 468-74 DOI: 10.1016/S1368-8375(01)00104-X PMID: 12110341
89. Vicent S et al (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours Br J Cancer 90(5) pp 1047-52 DOI: 10.1038/sj.bjc.6601644 PMID: 14997206 PMCID: 2409626
90. Burger R (2013) Impact of interleukin-6 in hematological malignancies Transfus Med Hemother 40(5) pp 336-43 DOI: 10.1159/000354194 PMID: 24273487 PMCID: 3822278
91. Niesvizky R et al (2006) Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma J Clin Oncol 24(18) pp 7545
92. Niesvizky R et al (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma Leuk Lymphoma 48(12) pp 2330-7 DOI: 10.1080/10428190701647887 PMID: 18067007
93. Mark T et al (2008) Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma Br J Haematol 143(5) pp 654-60 DOI: 10.1111/j.1365-2141.2008.07374.x PMID: 18950461 PMCID: 3626496
94. Niesvizky R et al (2002) Clarithromycin potentiates the response to dexamethasone in chemotherapy naïve multiple myeloma patients: a prospective, sequential, randomized trial Blood 100(11) pp abstract 5119
95. Fost DA et al (1999) Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy J Allergy Clin Immunology 103(6) pp 1031-5 DOI: 10.1016/S0091-6749(99)70175-2
96. Spahn JD et al (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study Ann Allergy Asthma Immunol 87(6) pp 501-5 DOI: 10.1016/S1081-1206(10)62264-8
97. Abe S et al (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells Am J Respir Cell Mol Biol 22(1) pp 51-60 DOI: 10.1165/ajrcmb.22.1.3400
98. Schmidt S et al (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance Cell Death Differ 11 (Suppl 1) pp S45-55 DOI: 10.1038/sj.cdd.4401456 PMID: 15243581
99. Laane E et al (2009) Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy Cell Death Differ 16(7) pp 1018-29 DOI: 10.1038/cdd.2009.46 PMID: 19390558
100. Yang ZJ et al (2011) The role of autophagy in cancer: therapeutic implications Mol Cancer Ther 10(9) pp 1533-41 DOI: 10.1158/1535-7163.MCT-11-0047 PMID: 21878654 PMCID: 3170456
101. Fung C et al 2008) Induction of autophagy during extracellular matrix detachment promotes cell survival Mol Biol Cell 19(3) pp 797-806 DOI: 10.1091/mbc.E07-10-1092 PMCID: 2262959
102. Puleston DJ and Simon AK (2014) Autophagy in the immune system Immunology 141(1) pp 1-8 DOI: 10.1111/imm.12165 PMCID: 3893844
103. Baginska J et al (2013) Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia Proc Natl Acad Sci U.S.A 110(43) pp 17450-5 DOI: 10.1073/pnas.1304790110 PMID: 24101526 PMCID: 3808626
104. Kikuchi T (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappaB transcription factors J Antimicrob Chemother 49(5) pp 745-55 DOI: 10.1093/jac/dkf008 PMID: 12003967
105. Shinkai M et al (2006) Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells Am J Physiol Lung Cell Mol Physiol 290(1) pp L75-85 DOI: 10.1152/ajplung.00093.2005
106. Morikawa K et al (1996) Modulatory effect of antibiotics on cytokine production by human monocytes in vitro Antimicrob Agents Chemother 40(6) pp 1366-70 PMID: 8726002 PMCID: 163332
107. Takizawa H et al (1995) Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action Biochem Biophysi Res Commun 210(3) pp 781-6 DOI: 10.1006/bbrc.1995.1727
108. Kohyama T et al (1999) Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors Antimicrob Agents Chemother 43(4) pp 907-11 PMID: 10103198 PMCID: 89224
109. Basyigit I et al (2004) The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data Ann Pharmacother 38(9) pp 1400-5 DOI: 10.1345/aph.1D634 PMID: 15252191
110. Pukhalsky AL et al (2004) Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease Mediators Inflamm 13(2) pp 111-7 DOI: 10.1080/09629350410001688495 PMID: 15203552 PMCID: 1781547
111. Crabtree JE et al (1993) Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection Scand J Immunol 37(1) pp 65-70 DOI: 10.1111/j.1365-3083.1993.tb01666.x PMID: 8418474
112. Peek RM Jr (2001) IV. Helicobacter pylori strain-specific activation of signal transduction cascades related to gastric inflammation Am J Physiol Gastrointest Liver Physiol 280(4) pp G525-30 PMID: 11254477
113. Shimada T and Terano A (1998) Chemokine expression in Helicobacter pylori-infected gastric mucosa J Gastroenterol 33(5) pp 613-7 DOI: 10.1007/s005350050146 PMID: 9773923
114. Aihara M et al (1997) Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45 Infect Immun 65(8) pp 3218-24 PMID: 9234778 PMCID: 1754551
115. Yasumoto K et al (1992) Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene J Biol Chem 267 (31) pp 22506-11 PMID: 1331059
116. Adachi T et al (1996) Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5 J Allergy Clin Immunol 98(6 Pt 2) pp S207-15 DOI: 10.1016/S0091-6749(96)70068-4 PMID: 8977529
117. Li Y et al (2002) Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice Chest 122(6) pp 2137-45 DOI: 10.1378/chest.122.6.2137PMID: 12475858
118. Morikawa K (1994) Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro Antimicrob Agents Chemother 38(11) pp 2643-7 DOI: 10.1128/AAC.38.11.2643 PMID: 7532933 PMCID: 188255
119. Morikawa K (2002) Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production Int J Antimicrob Agents 19(1) pp 53-9 DOI: 10.1016/S0924-8579(01)00457-5 PMID: 11814768
120. Williams AC (2005) Differential effects of three antibiotics on T helper cell cytokine expression J Antimicrob Chemother 56(3) pp 502-6 DOI: 10.1093/jac/dki251 PMID: 16006447
121. Sugiyama K et al (2007) Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells Clin Exp Immunol 147(3) pp 540-6 DOI: 10.1111/j.1365-2249.2007.03299.x PMID: 17302905 PMCID: 1810497
122. Gimbrone MA Jr et al (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea J Natl Cancer Inst 52(2) pp 413-27 PMID: 4816003
123. Ma XH et al (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma J Clin Invest 124(3) pp 1406-17 DOI: 10.1172/JCI70454 PMID: 24569374 PMCID: 3934165
124. Levy JM et al (2014) Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors Cancer Discov 4(7) pp 773-80 DOI: 10.1158/2159-8290.CD-14-0049 PMID: 24823863 PMCID: 4090283
125. Matsumoto T, Iida M and Shimizu M (1997) Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori Lancet 350(9071) pp 115-6 DOI: 10.1016/S0140-6736(05)61818-1 PMID: 9228971
126. Steinbach G et al (1999) Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial Ann Intern Med 131(2) pp 88-95 DOI: 10.7326/0003-4819-131-2-199907200-00003 PMID: 10419446
127. Papa A et al (2000) Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: a long-term follow-up study J Clin Gastroenterol 31(2) pp 169-71 DOI: 10.1097/00004836-200009000-00018 PMID: 10993438
128. Thiede C et al (2001) Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma J Clin Oncol 19(6) pp 1600-9 PMID: 11250988
129. Matsumoto T and Iida M (2005) [Extra-gastric lymphoma of MALT type and H pylori eradication] Nihon Rinsho Japanese J Clin Med 63 (Suppl 1) pp 308-11